Wall Street Analyst Upgrade Gilead Sciences Inc. [GILD]. What else is Wall St. saying


Gilead Sciences Inc. [NASDAQ: GILD] gained 1.86% or 1.28 points to close at $69.97 with a heavy trading volume of 8850408 shares. The company report on November 19, 2021 that Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta.

— If Approved, Bulevirtide Will Be the First Treatment Option for Adult Patients in the U. S. With Chronic Hepatitis Delta Virus Infection With Compensated Liver Disease –.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Gilead Sciences, Inc. (Nasdaq: GILD) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bulevirtide for injection (2 mg), a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease; bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA. Bulevirtide is an investigational agent in the U.S. and the safety and efficacy have not been established. The BLA submission is supported by data from completed and ongoing Phase 2 studies and the ongoing Phase 3 MYR301 study which supports the safety and efficacy of bulevirtide 2 mg once daily after 24 weeks of therapy. In Europe, Hepcludex® (bulevirtide) has been granted Conditional Marketing Authorization by the European Commission and PRIority MEdicines (PRIME) scheme eligibility by the European Medicines Agency (EMA), as the first approved treatment in Europe for adults with chronic HDV infection with compensated liver disease.

It opened the trading session at $68.70, the shares rose to $70.36 and dropped to $67.95, the range by which the price of stock traded the whole day. The daily chart for GILD points out that the company has recorded 5.65% gains over the past six months. However, it is still -23.71% lower than its most recent low trading price.

If we look at the average trading volume of 6.42M shares, GILD reached to a volume of 8850408 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Gilead Sciences Inc. [GILD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $76.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BMO Capital Markets have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 19, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on November 19, 2021, representing the official price target for Gilead Sciences Inc. stock. On July 30, 2021, analysts increased their price target for GILD shares from 81 to 84.

The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.22, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.15. The Price to Book ratio for the last quarter was 4.09, with the Price to Cash per share for the same quarter was set at 4.64. Price to Free Cash Flow for GILD in the course of the last twelve months was 14.63 with Quick ratio for the last quarter at 1.20.

Trading performance analysis for GILD stock

Gilead Sciences Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.12. With this latest performance, GILD shares gained by 4.06% in over the last four-week period, additionally plugging by 5.65% over the last 6 months – not to mention a rise of 16.40% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 64.95, with the RSI for the last a single of trading hit 74.12, and the three-weeks RSI is set at 59.31 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 68.23, while it was recorded at 68.16 for the last single week of trading, and 67.54 for the last 200 days.

Gilead Sciences Inc. [GILD]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +42.38 and a Gross Margin at +81.70. Gilead Sciences Inc.’s Net Margin is presently recorded at +0.50.

Return on Total Capital for GILD is now 21.25, given the latest momentum, and Return on Invested Capital for the company is 0.27. Return on Equity for this stock inclined to 0.60, with Return on Assets sitting at 0.19. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 176.45. Additionally, GILD Total Debt to Total Capital is recorded at 63.83, with Total Debt to Total Assets ending up at 46.95. Long-Term Debt to Equity for the company is recorded at 160.71, with the Long-Term Debt to Total Capital now at 58.14.

Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $9,044 per employee. Receivables Turnover for the company is 5.81 with a Total Asset Turnover recorded at a value of 0.38.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.

Gilead Sciences Inc. [GILD]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Gilead Sciences Inc. posted 2.19/share EPS, while the average EPS was predicted by analysts to be reported at 2.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 1.32%.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Gilead Sciences Inc. [GILD]

There are presently around $70,239 million, or 82.70% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 120,982,349, which is approximately -2.28% of the company’s market cap and around 0.10% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 114,548,108 shares of the stock with an approximate value of $7.87 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $7.23 billion in GILD stock with ownership of nearly 0.178% of the company’s market capitalization.

Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 729 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 63,891,245 shares. Additionally, 688 investors decreased positions by around 42,137,298 shares, while 229 investors held positions by with 916,520,502 shares. The mentioned changes placed institutional holdings at 1,022,549,045 shares, according to the latest SEC report filing. GILD stock had 122 new institutional investments in for a total of 7,858,972 shares, while 87 institutional investors sold positions of 2,331,358 shares during the same period.